Esophagus to Small Intestine

Endoscopy. 2023;55(6):491–8

Vithayathil M, Modolell I, Ortiz-Fernandez-Sordo J, Pappas A, Januszewicz W, O’Donovan M, Bianchi M, White JR, Kaye P, Ragunath K, di Pietro M

The effect of procedural time on dysplasia detection rate during endoscopic surveillance of Barrett’s esophagus

Background: Endoscopic surveillance of Barrett’s esophagus (BE) with Seattle protocol biopsies is time-consuming and inadequately performed in routine practice. There is no recommended procedural time for BE surveillance. The authors investigated the duration of surveillance procedures with adequate tissue sampling and effect on dysplasia detection rate (DDR).
Methods: They performed post-hoc analysis from the standard arm of a crossover randomized controlled trial recruiting patients with BE (≥ C2 and/or ≥ M3) and no clearly visible dysplastic lesions. After inspection with white-light imaging, targeted biopsies of subtle lesions and Seattle protocol biopsies were performed. Procedure duration and biopsy number were stratified by BE length. The effect of endoscopy-related variables on DDR was assessed by multivariable logistic regression.
Results: Of 142 patients recruited, 15 (10.6%) had high-grade dysplasia/intramucosal cancer and 15 (10.6%) had low-grade dysplasia. The median procedural time was 16.5 minutes (interquartile range, 14.0–19.0 minutes). Endoscopy duration increased by 0.9 minutes for each additional 1 cm of BE length. Seattle protocol biopsies had higher sensitivity for dysplasia than targeted biopsies (86.7% vs. 60.0%; p = 0.045). Longer procedural time was associated with increased likelihood of dysplasia detection on quadrantic biopsies (odds ratio [OR] = 1.10, 95% confidence interval [CI]: 1.00–1.20; p = 0.04), and for patients with BE > 6 cm also on targeted biopsies (OR = 1.21, 95% CI: 1.04–1.40; p = 0.01).

Conclusions: In Barrett’s esophagus patients with no clearly visible dysplastic lesions, longer procedural time was associated with increased likelihood of dysplasia detection. Adequate time slots are required to perform good-quality surveillance and maximize dysplasia detection.

Dr. M. di Pietro, Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK, E-Mail:

DOI: 10.1055/a-2015-8883

Back to overview

this could be of interest:

Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: Two multicenter, open-label, randomized controlled, non-inferiority trials

Lancet Gastroenterol Hepatol. 2023;8(7):623–34

Association of proton-pump inhibitor use with incident dementia and cognitive decline in older adults: A prospective cohort study

Gastroenterology. 2023;165(3):564–72.e1

More articles on the topic